Quick Summary
Researchers studied tiny particles called extracellular vesicles found in the blood of ME/CFS patients and compared them to healthy controls. They found that ME/CFS patients had more of these particles and they contained different levels of immune chemicals, particularly one called IL2. Using computer algorithms to analyze 20 different blood proteins, they could correctly identify ME/CFS patients about 86% of the time, suggesting that blood tests might one day help diagnose this condition.
Why It Matters
This research provides objective biomolecular evidence supporting ME/CFS as a disease with measurable physiological abnormalities, moving beyond subjective symptom reporting. The identification of potential blood-based biomarkers could facilitate earlier diagnosis and enable stratification of ME/CFS subtypes, while the immune and hemostasis pathway findings suggest specific therapeutic targets worth investigating.
Observed Findings
What the study reports it measured.
- ME/CFS cases exhibited significantly greater size and concentration of extracellular vesicles in plasma compared to controls.
- Interleukin-2 (IL2) content was significantly elevated in EVs from ME/CFS cases.
- Pro-inflammatory cytokines CSF2 and TNFα showed positive correlations with fatigue and physical symptom severity in ME/CFS patients.
- Serine protease SERPINA5 (involved in hemostasis) correlated with better self-reported general health scores in ME/CFS cases.
- Machine learning models using 7-20 proteins achieved 79-86% accuracy in distinguishing ME/CFS cases from controls.
Inferred Conclusions
What the authors interpret from those results.
- Extracellular vesicle composition and concentration are objectively altered in ME/CFS, suggesting potential utility as biomarkers.
- Immune dysregulation (elevated pro-inflammatory cytokines) and hemostasis abnormalities are implicated in ME/CFS pathophysiology and correlate with clinical severity.
- Multi-protein signatures can discriminate ME/CFS cases from controls with high accuracy, supporting development of blood-based diagnostic approaches.
- The interconnected alterations in EV cytokines, plasma cytokines, and proteomics indicate complex, system-wide biological disturbance in ME/CFS rather than isolated dysfunction.
Remaining Questions
- Can these biomarkers be validated in prospective, independent cohorts of adequate size to establish clinical diagnostic utility?
- Do the identified proteins and pathways represent primary disease mechanisms or secondary compensatory responses to an underlying trigger?
- How do these biomarker signatures change over time within individual patients, and do they correlate with symptom fluctuation or response to interventions?
- Can machine learning classifiers developed here generalize to genetically or geographically diverse ME/CFS populations, and what is their performance in distinguishing ME/CFS from similar conditions like post-viral syndromes?
What This Study Does Not Prove
This study identifies associations between proteins and ME/CFS but does not prove these proteins cause the disease or are directly responsible for symptoms. Machine learning accuracy, while promising, does not establish clinical utility in routine diagnostics without further validation in independent cohorts. The correlations observed do not determine whether immune dysregulation is a primary cause or a secondary consequence of ME/CFS pathophysiology.
Explore further
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Cite this study
The first block is for the primary paper and is the citation you should use in research work. The atlas-snapshot line only applies if you are specifically referring to this atlas’s reading of the paper on the date shown.
Primary citation
Giloteaux, Ludovic, Li, Jiayin, Hornig, Mady, Lipkin, W Ian, Ruppert, David, & Hanson, Maureen R (2023). Proteomics and cytokine analyses distinguish myalgic encephalomyelitis/chronic fatigue syndrome cases from controls.. Journal of translational medicine. https://doi.org/10.1186/s12967-023-04179-3
BibTeX
@article{mecfsatlas-giloteaux-2023-proteomics-cytokine,
author = {Giloteaux, Ludovic and Li, Jiayin and Hornig, Mady and Lipkin, W Ian and Ruppert, David and Hanson, Maureen R},
title = {Proteomics and cytokine analyses distinguish myalgic encephalomyelitis/chronic fatigue syndrome cases from controls.},
journal = {Journal of translational medicine},
year = {2023},
doi = {10.1186/s12967-023-04179-3},
note = {PubMed: 37179299},
url = {https://www.mecfsatlas.com/evidence/giloteaux-2023-proteomics-cytokine},
}Atlas snapshot reference
ME/CFS Atlas. Generator v1 / Scanner v1.4 / policy v0.1. Accessed 2026-11-14. https://www.mecfsatlas.com/evidence/giloteaux-2023-proteomics-cytokine
Contribute
Private, reviewed by a human. Not a public comment thread.